1. Signaling Pathways
  2. MAPK/ERK Pathway
  3. MAP3K

MAP3K

MAP3Ks (Mitogen-activated protein kinase kinase kinases), the top components of MAPK cascades, modulate many biological processes, such as growth, development and various environmental stresses. Based on the sequence of their kinase catalytic domain, MAP3Ks are classified into three groups: the MEKK-like, ZIK-like and Raf-like families. Raf-like MAP3Ks constitute largest MAP3K subfamily. Raf-like MAP3Ks play roles in response to biotic and abiotic stresses.

MAP3Ks often bind to both MAP4Ks and MAP2Ks in the same pathway. For example, MEKK1 (MAP3K1) binds to both the MAP4K NIK and the MAP2K MKK4, while NSY-1 (MAP3K) binds to the MAP2K SEK-1. MAP3Ks activates MAP2Ks by phosphorylation of a serine and/or threonine, and MAP2Ks activate MAPKs by dual phosphorylation of a Thr-X-Tyr motif.

MAP3K Isoform Specific Products:

  • MAP3K5/ASK1

  • MAP3K7/TAK1

MAP3K Related Products (12):

Cat. No. Product Name Effect Purity
  • HY-103490
    Takinib Inhibitor 98.00%
    Takinib is a potent and selective TAK1 inhibitor with an IC50 of 9.5 nM, which inhibits autophosphorylated and non-phosphorylated TAK1 that binds within the ATP-binding pocket and inhibits by slowing down the rate-limiting step of TAK1 activation.
  • HY-18938
    Selonsertib Inhibitor 99.12%
    Selonsertib, an orally bioavailable, selective apoptosis signal-regulating kinase 1 (ASK1) inhibitor with a pIC50 of 8.3, has been evaluated as an experimental treatment for diabetic nephropathy and kidney fibrosis.
  • HY-15434
    NG25 Inhibitor 99.45%
    NG25 is a potent dual TAK1 and MAP4K2 inhibitor, with IC50s of 149 nM and 21.7 nM, respectively.
  • HY-12686
    5Z-7-Oxozeaenol Inhibitor >99.0%
    5Z-7-Oxozeaenol is a natural anti-protozoan compound from fungal origin, acting as a potent irreversible and selective inhibitor of TAK1 and VEGF-R2, with IC50s of 8 nM and 52 nM, respectively.
  • HY-32018
    Cot inhibitor-2 Inhibitor 99.20%
    Cot inhibitor-2 is a COT/Tpl2 inhibitor.
  • HY-114332
    GNE-8505 Inhibitor
    GNE-8505 is an orally available inhibitor of Dual leucine zipper kinase (DLK).
  • HY-12947
    GNE-3511 Inhibitor 99.98%
    GNE-3511 is a dual leucine zipper kinase (DLK) inhibitor with a Ki of 0.5 nM.
  • HY-100844
    GS-444217 Inhibitor 99.80%
    GS-444217 is a potent, orally available and selective ATP-competitive inhibitor of apoptosis signal-regulating kinase 1 (ASK1) with an IC50 of 2.87 nM.
  • HY-19566
    NQDI-1 Inhibitor
    NQDI-1 inhibits apoptosis signal-regulating kinase 1 (ASK1) with a Ki of 500 nM and an IC50 of 3 μM.
  • HY-77251
    TAK1/MAP4K2 inhibitor 1 Inhibitor 99.70%
    TAK1/MAP4K2 inhibitor 1 is a potent dual TGFβ-activated kinase 1 (TAK1) and mitogen-activated protein kinase kinase kinase kinase 2 (MAP4K2) inhibitor, with IC50s of 41.1 nM and 18.2 nM, respectively.
  • HY-32015
    Cot inhibitor-1 Inhibitor
    Cot inhibitor-1 is a COT/Tpl2 inhibitor.
  • HY-114331
    DLK-IN-1 Inhibitor 99.47%
    DLK-IN-1 is a selective, orally active inhibitor of dual leucine zipper kinase (DLK, MAP3K12), with a Ki of 3 nM. DLK-IN-1 retains excellent CNS penetration and is well tolerated following multiple days of dosing at concentrations that exceed those required for DLK inhibition in the brain. DLK-IN-1 has activity in a model of Alzheimer’s Disease.
Isoform Specific Products

Your Search Returned No Results.

Sorry. There is currently no product that acts on isoform together.

Please try each isoform separately.